The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, the APOE*3Leiden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cardiovasc Med
Main Authors: Pouwer, Marianne G., Pieterman, Elsbet J., Verschuren, Lars, Caspers, Martien P. M., Kluft, Cornelis, Garcia, Ricardo A., Aman, Jurjan, Jukema, J. Wouter, Princen, Hans M. G.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Cardiovascular Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005845/
https://ncbi.nlm.nih.gov/pubmed/29946549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcvm.2018.00055
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados